NasdaqGM - Nasdaq Real Time Price USD

Skye Bioscience, Inc. (SKYE)

Compare
2.7000 -0.1600 (-5.59%)
At close: December 20 at 4:00:01 PM EST
3.0000 +0.30 (+11.11%)
After hours: December 20 at 5:01:03 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
28,166.3420
13,671.8010
12,106.4220
7,847.7140
6,289.0130
Operating Income
-28,166.3420
-13,671.8010
-12,106.4220
-7,847.7140
-6,289.0130
Net Non Operating Interest Income Expense
1,120.4360
-806.2960
-766.3500
-769.1560
-706.3560
Other Income Expense
5,815.4030
-23,163.0870
-6,602.0890
96.7880
436.2700
Pretax Income
-21,230.5030
-37,641.1840
-19,474.8610
-8,520.0820
-6,559.0990
Tax Provision
10.0710
3.6000
6.7410
2.1000
1.6000
Net Income Common Stockholders
-21,240.5740
-37,644.7840
-19,481.6020
-8,522.1820
-6,560.6990
Average Dilution Earnings
--
--
--
--
-345.4730
Diluted NI Available to Com Stockholders
-21,240.5740
-37,644.7840
-19,481.6020
-8,522.1820
-6,906.1720
Basic EPS
0.53
-5.37
-8.77
-5.00
-7.50
Diluted EPS
0.53
-5.37
-8.77
-5.00
-7.50
Basic Average Shares
29,588.4940
7,006.0380
2,221.0800
1,626.3970
922.9870
Diluted Average Shares
29,588.4940
7,006.0380
2,221.0800
1,626.3970
925.6830
Total Operating Income as Reported
-23,612.8740
-34,735.1730
-18,311.7320
-7,847.7140
-6,289.0130
Total Expenses
28,166.3420
13,671.8010
12,106.4220
7,847.7140
6,289.0130
Net Income from Continuing & Discontinued Operation
-21,240.5740
-37,644.7840
-19,481.6020
-8,522.1820
-6,560.6990
Normalized Income
-25,836.4827
-20,438.7404
-14,265.9517
-8,592.8372
-6,879.1761
Interest Income
2,581.5440
99.9740
19.0110
0.0030
0.0290
Interest Expense
1,438.4020
897.2070
663.7740
769.1590
704.8750
Net Interest Income
1,120.4360
-806.2960
-766.3500
-769.1560
-706.3560
EBIT
-19,792.1010
-36,743.9770
-18,811.0870
-7,750.9230
-5,854.2240
EBITDA
-19,640.3830
-36,619.7260
-18,696.0890
-7,716.7920
-5,852.3520
Reconciled Depreciation
151.7180
124.2510
114.9980
34.1310
1.8720
Net Income from Continuing Operation Net Minority Interest
-21,240.5740
-37,644.7840
-19,481.6020
-8,522.1820
-6,560.6990
Total Unusual Items Excluding Goodwill
5,817.6060
-21,779.8020
-6,602.0890
96.7880
436.2700
Total Unusual Items
5,817.6060
-21,779.8020
-6,602.0890
96.7880
436.2700
Normalized EBITDA
-25,457.9890
-14,839.9240
-12,094.0000
-7,813.5800
-6,288.6220
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
1,221.6973
-4,573.7584
-1,386.4387
26.1328
117.7929
12/31/2020 - 1/6/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OVID Ovid Therapeutics Inc.
0.9991
-2.05%
 
DNLI Denali Therapeutics Inc.
21.45
-0.19%
 
WVE Wave Life Sciences Ltd.
13.51
+2.43%
 
FDMT 4D Molecular Therapeutics, Inc.
6.31
+9.17%
 
RYTM Rhythm Pharmaceuticals, Inc.
56.12
+1.15%
 
TNGX Tango Therapeutics, Inc.
3.1000
+5.44%
 
ZLDPF Zealand Pharma A/S
100.51
-0.48%
 
ERNA Eterna Therapeutics Inc.
0.2501
+1.05%
 
SEPN Septerna, Inc.
24.28
+3.76%
 
CYTK Cytokinetics, Incorporated
48.87
+4.56%